[Betahistine treatment of Menière's disease (author's transl)].
An evaluation of Betahistine hydrochloride treatment of 92 patients suffering from Menière disease and Menière-like syndrom is presented. Observed for more than one year 54 (89%) patients showed complete relief of vertigo-attack symptoms. 7 (12%) patients showed a distinct improvement in their hearing as reflected in their audiograms, only 7 (12%) patients showed a further loss of hearing. There appeared to be a trend toward further improvement when therapy was maintained over at least a period of 3--4 month. Vertigo seemed to be the symptom most responsive to treatment and tinnitus the most resistant. Minimal side effects were observed in 17 (18%) patients.
D001621:Betahistine / Q000627:therapeutic use*; D003638:Deafness / Q000188:drug therapy; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008575:Meniere Disease / Q000188:drug therapy*; D011725:Pyridines / Q000627:therapeutic use*; D014012:Tinnitus / Q000188:drug therapy; D014717:Vertigo / Q000188:drug therapy
D011725:Pyridines; D001621:Betahistine
Erfahrungsbericht über Betahistin-Anwendung bei Morbus Menière.